Volixibat trial for itch from primary biliary cholangitis
Part of Digestive system, Skin clinical trials.
This Phase 2 study tests whether volixibat can safely reduce itching caused by primary biliary cholangitis (PBC). If you have PBC-related itch that persists, this trial may help you find a new treatment option.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You can sign consent and agree to attend all study visits through the end
- You are age 18 or older
- You have a confirmed PBC diagnosis based on standard guideline criteria
- Your itching is believed to be caused by PBC (not another cause), based on a required itch score
- You may use certain itch or liver-related medicines only if you also meet the study’s additional rules
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new medication, TH104, to see if it can reduce itching caused by primary biliary cholangitis (PBC). Itching is a common symptom of PBC, and this study aims to find a more effective treatment.
This trial tests whether adding fenofibrate to ursodeoxycholic acid (UDCA) can improve liver test results in people with primary biliary cholangitis (PBC) who did not respond enough to UDCA alone. It aims to see if the combination works better and is safe for adults with persistent, abnormal liver markers.
This research study tracks how well Primary Biliary Cholangitis (PBC) responds to standard medication (UDCA) and what happens to patients' health over time. It may help doctors understand which treatments work best for different people.
This trial tracks how well the combination of ursodiol and seladelpar works in people with primary biliary cholangitis (PBC), a liver disease. It aims to see if this treatment helps control symptoms and liver function.
This trial tests an experimental drug (CS0159) for people with primary biliary cholangitis (PBC) who either didn't respond well to or couldn't take the standard treatment UDCA. It aims to improve liver function and reduce symptoms.
This trial looks at whether slowly reducing UDCA (a medication for primary biliary cholangitis) is safe and still helpful in people whose liver tests have improved. It may help some patients avoid higher doses if their disease is well controlled.
Hear when a new Primary Biliary Cholangitis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.